Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine and Sertraline for Stereotypies in Mental Retardation
NCT00004300Phase 2Suspended
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bromocriptine and sertraline in stereotypic movement disorder (SMD) and Self-injurious behavior (3 arms), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoint: Frequency of Stereotyped Behavior. Status: suspended.
02
Drugs
bromocriptinesertraline
03
Conditions
stereotypic movement disorder (SMD)Self-injurious behavior
Beyond the preview
Go deeper on NCT00004300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004300.